Trials begin of VNS (vagus nerve stimulator) in obesity and Alzheimer's:
This article was originally published in Clinica
Executive Summary
Researchers have carried out the first human implants in studies to assess Cyberonics' vagus nerve stimulator as a treatment for two new indications - Alzheimer's disease and obesity. The NeuroCybernetic Prosthesis, which is already FDA-approved for treating epilepsy, was last month implanted in the first of six patients, as part of the first phase of a US study to assess the device in people with obesity. The Houston, Texas-based company said that the first of 10 Alzheimer's patients scheduled to take part in a pilot study in Sweden also received the device last month.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.